Revance Therapeutics intends to price initial public offering of stock

Deal funds research, development, clinical trials, RT001 development

By Devika Patel

Knoxville, Tenn., Dec. 31 - Revance Therapeutics, Inc. plans to price an initial public sale of its common stock with a greenshoe, according to a Form S-1 filed Tuesday with the Securities and Exchange Commission.

Cowen and Co. and Piper Jaffray are the joint bookrunners.

Proceeds will be used for research and development, clinical trials, to make payments on a term loan agreement with Hercules Technology Growth Capital, Inc., to make payments under an agreement with Medicis Pharmaceutical Corp., for development of RT001, working capital and other general corporate purposes.

The clinical stage specialty biopharmaceutical company is based in Newark, Calif. It expects its shares will trade on the Nasdaq under the symbol "RVNC."

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.